Nowadays, Lokivetmab is a topic that has captured the attention of many people around the world. From its impact on society to its influence on the economy, Lokivetmab is a topic that has become increasingly relevant in everyday conversations. With the increasing importance of Lokivetmab, it is crucial to understand its scope and implications in different aspects of life. In this article, we will thoroughly explore Lokivetmab and analyze its impact on our modern society. From its origins to its possible future developments, we will delve into the fascinating world of Lokivetmab and discover its true meaning in today's world.
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Target | interleukin 31 (IL-31) |
Clinical data | |
Trade names | Cytopoint |
Routes of administration | subcutaneous injection |
ATCvet code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
UNII |
Lokivetmab, trade name Cytopoint, is a monoclonal antibody used to treat atopic dermatitis in dogs. It acts against interleukin 31 (IL-31), which is a cytokine involved in causing itchiness (pruritus). Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks.
The United States Department of Agriculture (USDA) approved lokivetmab (manufactured by Zoetis and sold under the trade name Cytopoint) in December 2016, and it was approved by the European Medicines Agency in 2017. Lokivetmab was the first monoclonal antibody to be approved for use in animals in the European Union.